New treatment ‘increases chance of survival’ for prostate cancer patients

A total of 150 people took part in the trial, published in the journal European Urology, run by the Southampton Clinical Trials Unit (SCTU) which is based at the University of Southampton’s Centre for Cancer Immunology.

Patients with advanced prostate cancer have a greater chance of survival if treated with a targeted cancer drug in addition to chemotherapy, according to a new study.

Analysis of the study funded by Cancer Research UK and AstraZeneca UK found that adding the drug capivasertib to chemotherapy can improve survival rates for men whose cancer had spread to other parts of the body.